127 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury (“AKI”) associated with respiratory virus infection.
Our focus is on developing … of hyperuricemia and then maintain purine metabolism at a low level during viral infection and target management of acute organ injury. Our XRx-008 program
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
for XRx-101 product candidate program in the treatment of acute kidney injury (“AKI”) in respiratory virus infections. We may experience delays in our … , the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
kidney and other acute organ injury associated with Respiratory Viral infection. In addition, XRx-225 is a pre-clinical stage program for Type 2
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
such as autosomal dominant polycystic kidney disease (“ADPKD”) and larger, more prevalent type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury … management of acute organ injury. Our XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors (“XOI
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
prevalent type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury (“AKI”) associated with respiratory virus infection.
Our focus … of hyperuricemia and then maintain purine metabolism at a low level during viral infection and target management of acute organ injury. Our XRx-008 program
424B3
kmtoe5cr2okb sjv
13 Jun 24
Prospectus supplement
4:11pm
424B3
2pqzru
13 Jun 24
Prospectus supplement
4:10pm
424B3
8lm7t6ag79b 9tvvnci
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.1
laxhazm idjg
12 Jun 24
Current report (foreign)
7:00am
6-K
EX-99.1
5v03zk06fcdawp2t1it
4 Jun 24
XORTX to Present at BIO International Convention 2024
8:30am
6-K
EX-99.1
eif 0xnexyal9zmkb
17 May 24
Current report (foreign)
7:00pm
6-K
EX-99.2
r7op7s4nyl06dn9z7
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
ro8w1t96
30 Apr 24
Current report (foreign)
2:58pm
6-K
EX-99.1
v1363ncf1ap 371
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-99.1
nzxv2j2k9zef5cv 0q3n
8 Apr 24
XORTX Welcomes New Member to the Board of Directors
7:30am
6-K
EX-99.1
lwqjeqh85245xb
8 Apr 24
XORTX Announces Participation in Spring 2024 Investor Conferences
7:00am
6-K
EX-99.1
exkbk evfq
27 Mar 24
XORTX Announces New Clinical Advisory Board Member
7:42am
6-K
EX-99.1
woaqtputbnnd7a wy
3 Jan 24
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
7:25am